Targeting CXCL16 and STAT1 augments immune checkpoint blockade therapy in triple-negative breast cancer

Chemotherapy prior to immune checkpoint blockade (ICB) treatment appears to improve ICB efficacy but resistance to ICB remains a clinical challenge and is attributed to highly plastic myeloid cells associating with the tumor immune microenvironment (TIME). Here we show by CITE-seq single-cell transc...

Descripción completa

Detalles Bibliográficos
Autores principales: Palakurthi, Bhavana, Fross, Shaneann R., Guldner, Ian H., Aleksandrovic, Emilija, Liu, Xiyu, Martino, Anna K., Wang, Qingfei, Neff, Ryan A., Golomb, Samantha M., Lewis, Cheryl, Peng, Yan, Howe, Erin N., Zhang, Siyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101955/
https://www.ncbi.nlm.nih.gov/pubmed/37055410
http://dx.doi.org/10.1038/s41467-023-37727-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10101955/
https://www.ncbi.nlm.nih.gov/pubmed/37055410
http://dx.doi.org/10.1038/s41467-023-37727-y

Ejemplares similares